JP7109675B2 - 植込み型徐放微細針パッチ及びその調製方法 - Google Patents
植込み型徐放微細針パッチ及びその調製方法 Download PDFInfo
- Publication number
- JP7109675B2 JP7109675B2 JP2021536138A JP2021536138A JP7109675B2 JP 7109675 B2 JP7109675 B2 JP 7109675B2 JP 2021536138 A JP2021536138 A JP 2021536138A JP 2021536138 A JP2021536138 A JP 2021536138A JP 7109675 B2 JP7109675 B2 JP 7109675B2
- Authority
- JP
- Japan
- Prior art keywords
- needle tip
- mold
- needle
- water
- implantable sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 28
- 238000002347 injection Methods 0.000 claims description 89
- 239000007924 injection Substances 0.000 claims description 89
- 239000010410 layer Substances 0.000 claims description 81
- 239000007788 liquid Substances 0.000 claims description 78
- 238000013268 sustained release Methods 0.000 claims description 52
- 239000012730 sustained-release form Substances 0.000 claims description 52
- 239000000463 material Substances 0.000 claims description 49
- 239000000243 solution Substances 0.000 claims description 46
- 229940079593 drug Drugs 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 33
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 29
- 239000004626 polylactic acid Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 17
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- -1 saccharide compounds Chemical class 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- 239000002861 polymer material Substances 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000003223 protective agent Substances 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 9
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- 239000012792 core layer Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229920005862 polyol Polymers 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 4
- 229920001661 Chitosan Chemical class 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 108010022355 Fibroins Proteins 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 4
- 239000004373 Pullulan Substances 0.000 claims description 4
- 229920001218 Pullulan Polymers 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 4
- 239000001099 ammonium carbonate Substances 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 229920001690 polydopamine Polymers 0.000 claims description 4
- 229920002643 polyglutamic acid Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 235000019423 pullulan Nutrition 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 229940105329 carboxymethylcellulose Drugs 0.000 description 8
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229920003169 water-soluble polymer Polymers 0.000 description 7
- 229960002941 etonogestrel Drugs 0.000 description 6
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229960000744 vinpocetine Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 3
- 229940022757 asiaticoside Drugs 0.000 description 3
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960003607 granisetron hydrochloride Drugs 0.000 description 3
- QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 description 1
- 229950011191 norgesterone Drugs 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
- B29C45/0001—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor characterised by the choice of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
- B29C45/16—Making multilayered or multicoloured articles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/04—General characteristics of the apparatus implanted
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0059—Degradable
- B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
- B29L2031/7544—Injection needles, syringes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/756—Microarticles, nanoarticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Manufacturing & Machinery (AREA)
- Mechanical Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Description
1)生分解可能な非水溶性の高分子材料と一部の有機溶媒とを混合し、細孔形成剤を加え又は加えず、保護剤を加え又は加えず、針先中心層の基質材料溶液を調製し、活性成分と残りの有機溶媒とを混合して薬物溶液を調製し、薬物溶液と針先中心層の基質材料溶液とを混合して、針先中心層用の金型注入用液体を得るステップと、
又は、
生分解可能な非水溶性の高分子材料と有機溶媒とを混合し、細孔形成剤を加え又は加えず、保護剤を加え又は加えず、活性成分を加えて均一に混合することで、針先中心層用の金型注入用液体を得るステップと、
2)水溶性の高分子材料と水とを混合し、小分子糖類又はポリオール類化合物を加え又は加えず、均一に混合することで、針先外層用の金型注入用液体を得、水溶性の高分子材料と水とを混合し、小分子糖類又はポリオール類化合物を加え又は加えず、均一に混合することで、針本体とベース用の金型注入用液体を得るステップと、
3)針先外層用の金型注入用液体を微細針用金型に注入して乾燥させることで、針先外層を調製し、前記針先中心層用の金型注入用液体を上記微細針用金型に注入して加熱することで有機溶媒を除去して冷却し、前記針本体とベース用の金型注入用液体を微細針用金型に注入して針本体とベースを調製して乾燥させ、そして離型させるステップと、
を含む上記した植込み型徐放微細針の調製方法をさらに提供する。
実施例1 ポリ乳酸類植込み型徐放微細針パッチの調製
実施例2 ポリ乳酸類植込み型徐放微細針パッチの調製
実施例3 ポリ乳酸類植込み型徐放微細針パッチの調製
実施例4 ポリ乳酸類植込み型徐放微細針パッチの調製
実施例5 針先中心層に細孔形成剤を加えたポリ乳酸類植込み型徐放微細針パッチの調製
実施例6-17
実施例18-28 小分子薬物の植込み型ポリ乳酸類徐放微細針パッチの調製
実施例36 アジアチコサイドの植込み型ポリ乳酸類徐放微細針パッチの調製
実施例37-42 化粧品成分を含む植込み型ポリ乳酸類徐放微細針パッチの調製
実施例44 ポリ乳酸類植込み型徐放微細針パッチの皮膚への植込み
Claims (10)
- 針先中心層と針先外層とを含む針先と、針本体と、ベースとを含み、前記針先中心層は、生分解可能な非水溶性の高分子材料を含む基質で形成され、前記針先外層,前記針本体及び前記ベースは、水溶性の高分子材料を含む基質で形成されることを特徴とする植込み型徐放微細針。
- 前記針先中心層は、少なくとも一つの活性成分を含み、前記生分解可能な非水溶性の高分子材料と活性成分との質量比は、0.5:1~1000:1であることを特徴とする、請求項1に記載の植込み型徐放微細針。
- 前記生分解可能な非水溶性の高分子材料は、ポリ乳酸,ポリ-L-乳酸,ポリ-DL-乳酸,ポリ乳酸・グリコール酸共重合体,ポリグリコール酸及びポリカプロラクトンの一つ又は複数であることを特徴とする、請求項1に記載の植込み型徐放微細針。
- 前記針先中心層の高さは、針先と前記針本体の高さの三分の二以下であることを特徴とする、請求項1に記載の植込み型徐放微細針。
- 前記針先中心層は、塩化ナトリウム,炭酸ナトリウム,炭酸水素ナトリウム,炭酸水素アンモニウム,トレハロース,マルトース,シクロデキストリン及びその誘導体,ポリメチルピロリドン,低分子量ヒアルロン酸及びそのナトリウム塩,低分子量セルロース類誘導体の一つ又は複数である細孔形成剤をさらに含み、前記細孔形成剤は、前記針先中心層の総質量の0.1%-10%を占め、前記針先中心層は、ポリヒドロキシ化合物,糖類化合物,血清アルブミン,ポリビニルピロリドン,コンドロイチン硫酸,アミノ酸の一つ又は複数である保護剤をさらに含み、前記保護剤は、前記針先中心層の総質量の0.1%-10%を占めることを特徴とする、請求項1に記載の植込み型徐放微細針。
- 前記水溶性の高分子材料は、カルボキシメチルセルロース,ヒドロキシプロピルメチルセルロース,ヒドロキシエチルセルロース,ポリビニルアルコール及びその誘導体,ポビドン及びその誘導体,ヒアルロン酸ナトリウム及びその誘導体,コンドロイチン硫酸,キトサン誘導体,ポリアクリルアミド誘導体,ポリグルタミン酸,ポリドーパミン,プルラン,ゼラチン,コラーゲン,フィブロインの一つ又は複数であり、前記水溶性の高分子材料は、分子量が20-2000kDaであることを特徴とする、請求項1に記載の植込み型徐放微細針。
- 前記針先外層,前記針本体及び前記ベースは、小分子量糖類とポリオール類化合物とをさらに含み、前記小分子量糖類とポリオール類化合物は、トレハロース,蔗糖,マルトース,ソルビトール,マンニトール,キシリトール,グリセリンの一つ又は複数であることを特徴とする、請求項1に記載の植込み型徐放微細針。
- 生分解可能な非水溶性の高分子材料と一部の有機溶媒とを混合し、細孔形成剤を加え又は加えず、保護剤を加え又は加えず、前記針先中心層の基質材料溶液を調製し、活性成分と残りの有機溶媒とを混合して薬物溶液を調製し、薬物溶液と前記針先中心層の基質材料溶液とを混合して、前記針先中心層用の金型注入用液体を得るステップと、
又は、
生分解可能な非水溶性の高分子材料と有機溶媒とを混合し、細孔形成剤を加え又は加えず、保護剤を加え又は加えず、活性成分を加えて均一に混合することで、前記針先中心層用の金型注入用液体を得るステップと、
水溶性の高分子材料と水とを混合し、小分子糖類又はポリオール類化合物を加え又は加えず、均一に混合することで、前記針先外層用の金型注入用液体を得、水溶性の高分子材料と水とを混合し、小分子糖類又はポリオール類化合物を加え又は加えず、均一に混合することで、前記針本体と前記ベース用の金型注入用液体を得るステップと、
前記針先外層用の金型注入用液体を微細針用金型に注入して乾燥させることで、前記針先外層を調製し、前記針先中心層用の金型注入用液体を微細針用金型に注入して加熱することで有機溶媒を除去して冷却し、前記針本体と前記ベース用の金型注入用液体を微細針用金型に注入して前記針本体と前記ベースを調製して乾燥させるステップと、
を含むことを特徴とする請求項1~請求項7のいずれか1項に記載の植込み型徐放微細針の製造方法。 - 請求項1~請求項7のいずれか1項に記載の植込み型徐放微細針と、バッキング材とを含むことを特徴とする植込み型徐放微細針パッチ。
- 病気の治療や予防,保健,美容の分野に適用されることを特徴とする、請求項9に記載の植込み型徐放微細針パッチ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811011984.8A CN110917176B (zh) | 2018-08-31 | 2018-08-31 | 一种可植入型缓释微针贴片及其制备方法 |
CN201811011984.8 | 2018-08-31 | ||
PCT/CN2019/103332 WO2020043168A1 (zh) | 2018-08-31 | 2019-08-29 | 一种可植入型缓释微针贴片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021535928A JP2021535928A (ja) | 2021-12-23 |
JP7109675B2 true JP7109675B2 (ja) | 2022-07-29 |
Family
ID=69642829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021536138A Active JP7109675B2 (ja) | 2018-08-31 | 2019-08-29 | 植込み型徐放微細針パッチ及びその調製方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210178138A1 (ja) |
EP (1) | EP3845216A4 (ja) |
JP (1) | JP7109675B2 (ja) |
CN (1) | CN110917176B (ja) |
WO (1) | WO2020043168A1 (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111388407B (zh) * | 2020-04-17 | 2021-02-12 | 南京鼓楼医院 | 一种基于多巴胺凝胶的微针阵列及其制备和应用 |
CN111450405A (zh) * | 2020-05-08 | 2020-07-28 | 无锡元旭生物技术有限公司 | 可溶性微针贴片原液的速配方法 |
CN113679692A (zh) * | 2020-05-15 | 2021-11-23 | 华中科技大学 | 一种可产生气体快速起效的微针阵列贴片及其制备与应用 |
CN111588689B (zh) * | 2020-06-20 | 2023-08-11 | 温州医科大学 | 一种角膜微创可溶性微针贴片及其制备方法与应用 |
CN111870806A (zh) * | 2020-07-22 | 2020-11-03 | 南方科技大学 | 一种磁控微针机器人及其制备方法、使用方法和应用 |
CN114146046B (zh) * | 2020-09-07 | 2024-03-01 | 中国科学院理化技术研究所 | 具有多层结构的涂层微针、其制备方法及包含该涂层微针的微针贴片 |
CN114324196B (zh) * | 2020-09-29 | 2024-06-11 | 华中科技大学 | 用于增强皮肤光透明性的可溶性聚合物微针的制备及应用 |
CN112244901B (zh) * | 2020-10-17 | 2021-12-24 | 安徽云飞芳植生物科技有限公司 | 模型钉发系统 |
CN112294750B (zh) * | 2020-10-29 | 2023-06-20 | 广东药科大学 | 一种吲哚美辛胶束复合微针及其制备方法 |
CN112494421B (zh) * | 2020-12-23 | 2022-09-20 | 华中科技大学 | 一种缓释可溶微针、制备方法及应用 |
CN112842989B (zh) * | 2021-01-20 | 2023-04-11 | 浙江理工大学 | 一种负载铜离子掺杂聚多巴胺的微针贴片及其制备方法、应用 |
CN115068427B (zh) * | 2021-03-11 | 2024-01-30 | 于荣敏 | 缓释7天及缓释14天的青蒿素b微球及其制备方法 |
CN113563642B (zh) * | 2021-06-28 | 2022-09-13 | 深圳职业技术学院 | 一种生物分析采样用复合微针及其制备方法 |
CN113856032A (zh) * | 2021-08-18 | 2021-12-31 | 厦门薇针医药科技有限公司 | 可溶微针湿膜及其制备方法 |
CN113599501B (zh) * | 2021-08-25 | 2022-11-29 | 北京三元基因药业股份有限公司 | 一种稳定的干扰素微针制剂及其制备方法与应用 |
CN114099414A (zh) * | 2021-11-19 | 2022-03-01 | 烟台魔技纳米科技有限公司 | 一种可控缓释药物的微针及其制备方法 |
TWI783807B (zh) | 2021-12-02 | 2022-11-11 | 怡定興科技股份有限公司 | 多層結構微針貼片及其製作方法 |
CN114146173B (zh) * | 2021-12-06 | 2024-04-26 | 中国药科大学 | 一种控释型微针贴片及其在脱敏治疗领域中的应用 |
CN114129506B (zh) * | 2021-12-07 | 2023-05-16 | 上海交通大学医学院附属第九人民医院 | 载积雪草苷微针及其在促进创面愈合中的应用 |
US20240189564A1 (en) * | 2021-12-31 | 2024-06-13 | Small'lab Co., Ltd. | Microneedles comprising hormone-containing surface-modified microspheres and method of preparing the same |
WO2023128280A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 스몰랩 | 표면개질 미립구를 포함하는 마이크로니들 및 그 제조방법 |
CN114259458B (zh) * | 2022-01-04 | 2023-09-22 | 上海忱扬生物科技有限公司 | 一种具有抗衰功效的超氧化物岐化酶可溶性微针贴片 |
CN116510014A (zh) * | 2022-01-28 | 2023-08-01 | 苏州悦肤达医疗科技有限公司 | 药物组合物、微针制剂、微针给药系统、制备方法和应用 |
CN114796091A (zh) * | 2022-03-12 | 2022-07-29 | 四川大学 | 用于降钙素皮下缓释的微针阵列及其制备方法 |
CN114917465B (zh) * | 2022-03-23 | 2024-04-09 | 深圳大学 | 一种自发热微针载药贴片及其制备方法 |
CN114848577B (zh) * | 2022-04-15 | 2024-07-23 | 兰州大学 | 一种用于治疗皮下肿瘤的双层导电微针贴片及其制备方法和应用 |
CN114917180B (zh) * | 2022-04-19 | 2023-11-14 | 中国医学科学院输血研究所 | 一种复合血小板裂解液的可溶性微针的制备方法及其用途 |
CN115671026A (zh) * | 2022-04-25 | 2023-02-03 | 复向丝泰医疗科技(苏州)有限公司 | 一种丝蛋白微针及其制备方法 |
CN114984435A (zh) * | 2022-05-20 | 2022-09-02 | 杭州诺莘科技有限责任公司 | 一种涂层修饰的海绵骨针经皮吸收组合物及其制备方法 |
CN114903843B (zh) * | 2022-06-02 | 2023-01-13 | 优微(珠海)生物科技有限公司 | 一种微针制剂、微针贴片及其制备方法 |
CN115475138B (zh) * | 2022-10-10 | 2024-09-03 | 中国医学科学院生物医学工程研究所 | 一种可分离并具有双层结构的可溶性微针贴片及其制备方法和应用 |
CN115581770B (zh) * | 2022-10-10 | 2024-08-27 | 江苏集萃新型药物制剂技术研究所有限公司 | 微针贴剂及其制备方法 |
CN115381767B (zh) * | 2022-10-27 | 2022-12-30 | 深圳青澜生物技术有限公司 | 一种用于预防或治疗皮肤感染的微针贴片及其制备方法 |
CN115414381B (zh) * | 2022-11-07 | 2023-03-28 | 西南民族大学 | 一种具有瘢痕抑制和/或促伤口愈合作用的组合物及其制备方法和用途 |
CN115487171A (zh) * | 2022-11-10 | 2022-12-20 | 郑州大学 | 一种透明质酸-异甘草素偶联物、溶解型微针贴及制备方法和应用 |
CN116650477B (zh) * | 2023-06-14 | 2023-11-10 | 黑龙江迪龙制药有限公司 | 用于抗血小板聚集的含奥扎格雷钠的药物组合物及其制备方法 |
CN116440062B (zh) * | 2023-06-15 | 2023-09-26 | 北京市心肺血管疾病研究所 | 一种搭载左西孟旦用于治疗心力衰竭的可溶性微针贴片及其制备方法 |
CN116869848A (zh) * | 2023-09-08 | 2023-10-13 | 中科微针(北京)科技有限公司 | 一种含积雪草活性成分的祛疤微针贴 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080508A1 (ja) | 2005-01-31 | 2006-08-03 | Bioserentach Co., Ltd. | 経皮吸収製剤、経皮吸収製剤保持シート、及び経皮吸収製剤保持用具 |
JP2016513649A (ja) | 2013-03-15 | 2016-05-16 | コリウム インターナショナル, インコーポレイテッド | 治療剤の送達のためのマイクロアレイおよび使用の方法 |
WO2017090254A1 (ja) | 2015-11-27 | 2017-06-01 | 株式会社ラボ・ジュヴェルサ | マイクロニードル及びその製造方法 |
CN106806354A (zh) | 2015-12-02 | 2017-06-09 | 中国科学院理化技术研究所 | 一种聚丙烯酸酯柔曲性溶胀微针 |
CN107811963A (zh) | 2016-09-13 | 2018-03-20 | 上海庚丰医药化工有限公司 | 可溶性微针系统及其应用 |
JP2018510170A (ja) | 2015-03-27 | 2018-04-12 | レオ ファーマ アクティーゼルスカブ | 有効成分を皮膚へ送達するためのマイクロニードルパッチ製剤 |
CN108325064A (zh) | 2018-03-02 | 2018-07-27 | 莆田学院 | 一种缓释微针及其制备方法 |
CN108392729A (zh) | 2018-04-20 | 2018-08-14 | 威海迈尼生物科技有限公司 | 一种接枝药物的交联透明质酸微针 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101687094B (zh) | 2005-09-06 | 2012-09-26 | 谢拉杰克特股份有限公司 | 含有药物颗粒和/或药物吸附颗粒的固体溶液穿孔器 |
CA2695731C (en) * | 2007-08-06 | 2018-04-03 | Transderm, Inc. | Microneedle arrays formed from polymer films |
CN104888343A (zh) | 2015-05-07 | 2015-09-09 | 北京化工大学 | 一种高分子实心微针及其批量制备方法 |
CN105596287B (zh) * | 2016-02-04 | 2018-09-18 | 广州新济药业科技有限公司 | 主动分离型可溶性微针及其制备方法 |
KR20190070335A (ko) * | 2016-11-23 | 2019-06-20 | 유니버시티 메디컬 파마슈티컬스 코퍼레이션 | 미세바늘 전달 시스템 및 방법 |
KR101776659B1 (ko) * | 2017-02-27 | 2017-09-11 | 주식회사 쿼드메디슨 | 마이크로 니들 및 이의 제조방법 |
-
2018
- 2018-08-31 CN CN201811011984.8A patent/CN110917176B/zh active Active
-
2019
- 2019-08-29 US US17/271,881 patent/US20210178138A1/en active Pending
- 2019-08-29 JP JP2021536138A patent/JP7109675B2/ja active Active
- 2019-08-29 EP EP19854281.3A patent/EP3845216A4/en active Pending
- 2019-08-29 WO PCT/CN2019/103332 patent/WO2020043168A1/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080508A1 (ja) | 2005-01-31 | 2006-08-03 | Bioserentach Co., Ltd. | 経皮吸収製剤、経皮吸収製剤保持シート、及び経皮吸収製剤保持用具 |
JP2016513649A (ja) | 2013-03-15 | 2016-05-16 | コリウム インターナショナル, インコーポレイテッド | 治療剤の送達のためのマイクロアレイおよび使用の方法 |
JP2018510170A (ja) | 2015-03-27 | 2018-04-12 | レオ ファーマ アクティーゼルスカブ | 有効成分を皮膚へ送達するためのマイクロニードルパッチ製剤 |
WO2017090254A1 (ja) | 2015-11-27 | 2017-06-01 | 株式会社ラボ・ジュヴェルサ | マイクロニードル及びその製造方法 |
CN106806354A (zh) | 2015-12-02 | 2017-06-09 | 中国科学院理化技术研究所 | 一种聚丙烯酸酯柔曲性溶胀微针 |
CN107811963A (zh) | 2016-09-13 | 2018-03-20 | 上海庚丰医药化工有限公司 | 可溶性微针系统及其应用 |
CN108325064A (zh) | 2018-03-02 | 2018-07-27 | 莆田学院 | 一种缓释微针及其制备方法 |
CN108392729A (zh) | 2018-04-20 | 2018-08-14 | 威海迈尼生物科技有限公司 | 一种接枝药物的交联透明质酸微针 |
Also Published As
Publication number | Publication date |
---|---|
WO2020043168A1 (zh) | 2020-03-05 |
US20210178138A1 (en) | 2021-06-17 |
EP3845216A1 (en) | 2021-07-07 |
CN110917176A (zh) | 2020-03-27 |
CN110917176B (zh) | 2021-03-30 |
JP2021535928A (ja) | 2021-12-23 |
EP3845216A4 (en) | 2022-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7109675B2 (ja) | 植込み型徐放微細針パッチ及びその調製方法 | |
WO2020043167A1 (zh) | 一种可快速植入型缓释微针贴片及其制备方法 | |
CN114146046B (zh) | 具有多层结构的涂层微针、其制备方法及包含该涂层微针的微针贴片 | |
JP6894455B2 (ja) | 治療剤の送達のためのマイクロアレイ、使用方法および製造方法 | |
CN110870943A (zh) | 一种可植入型两段式微针贴片及其制备方法 | |
JP6279662B2 (ja) | 微小突起アレイを使用した副甲状腺ホルモンの経皮送達のための方法及びデバイス | |
KR101747099B1 (ko) | 생체적합성 고분자를 이용한 마이크로니들의 제조방법 | |
Chen et al. | Long-acting microneedles: a progress report of the state-of-the-art techniques | |
ES2921174T3 (es) | Conjunto de microestructuras para el suministro de agentes activos, método de fabricación del conjunto de microestructuras y formulación líquida del mismo | |
US5736152A (en) | Non-polymeric sustained release delivery system | |
JP2016512754A5 (ja) | ||
WO2021244630A1 (zh) | 一种耐热型可植入式聚合物微针及其制备方法和应用 | |
TWI718576B (zh) | 溶解特性優秀的透明質酸微結構體 | |
JP2018502927A (ja) | マイクロニードルワクチンパッチ用ミョウバン含有コーティング製剤 | |
WO2017043627A1 (ja) | マイクロニードル製剤 | |
KR20170040767A (ko) | 용해성 마이크로니들 마스크 키트 | |
CN111544757A (zh) | 一种载抗血管瘤药物微针贴片及制备方法 | |
TW201714610A (zh) | 蛋白質或肽傳遞用的可溶性微針 | |
KR102652671B1 (ko) | 피임 마이크로니들용 미립구 조성물 및 이를 포함한 피임 마이크로니들 | |
WO2022215693A1 (ja) | 歯科用局所麻酔マイクロニードルアレイ | |
Queiroz et al. | Microneedles as an alternative technology for transdermal drug delivery systems: a patent | |
KR20170046043A (ko) | 백반증 치료제 전달을 위한 용해성 미세바늘 패치 | |
KR20170032809A (ko) | B형 간염 치료를 위한 용해성 미세바늘 패치 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220705 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220719 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7109675 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |